The application and efficacy of interventional therapy in managing distal cholangiocarcinoma

A comparion study of mid-long-term efficacy of biliary stent combined with arterial infusion and/or radiotherapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-14005439

Enrollment

Unknown

Registered

2014-11-04

Start date

2014-12-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma

Interventions

A:percutaneous biliary stent

B:percutaneous biliary stent with transcatheter arterial infusion

C:percutaneous biliary stent with transcatheter arterial infusion and intensity modulated radiation therapy

D:percutaneous biliary stent with transcatheter arterial infusion and implantation of particle chain

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. To be aged 18 to 80 years; 2. Histologic or cytologic evidence and images confirmed unresectable distal cholangiocarcinoma; 3. Good general conditions with Karnofsky score more than 60; 4. Expectied survival time longer than 3 months; 5. Normal function of heart, liver, kidney and bone marrow, Child-Pugh A or B; 6. Well toleration of percutaneous biliary drainage, stenting, implantation of particle chain, radiotheray and transcatheter arterial infusion; 7. compied with the plan of treatment and follow-up.

Exclusion criteria

Exclusion criteria: 1. Successful percutaneous biliary drainage of stenting before study; 2. Systemic of arterial chemotherapy in 4 weeks by study; 3. Radiation in distal bile duct or surrounding tissues before study; 4. Severe comorbidities: 4.1. Severe myocardiac infarction or arrhythmia; 4.2. Blood prssure unable controlled under 180/100mmHg; Glucose less than 2.7mmol/L or more than 22.2mmol/L; 4.3. Severe hepatic or renal diseases; 4.4. Severe chronic obstructive pulmonary disease; 4.5. Other severe diseases needed treatment opposed to intervention of study; 5. Severe adverse event related to contrast agent or chemotherapeutics; 6. Pregnant women, nursing mothers and childbearing-age women planning to conceive; 7. Any psychiatric or other disease may affect informed consent of the patients for test.

Design outcomes

Primary

Measure	Time frame
overall survival time;	—

Secondary

Measure	Time frame
patent time of bile duct;progression-free survival time;	—

Countries

China

Contacts

Public ContactHan Xin-Wei

hanxinwei2006@163.com13803842129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026